title: Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.
abstract: Allogeneic bone marrow transplantation (BMT) is considered to be the only curative therapy for chronic myelogenous leukemia (CML). The cytogenetic marker of CML, the Philadelphia (Ph) chromosome, or the molecular alterations caused by the BCR-ABL gene fusion can be used to monitor the success of treatment. A sensitive two-step reverse-transcription polymerase chain reaction (RT-PCR) was done to score BCR-ABL-mRNA-positive leukemic cells in frozen bone marrow samples of 15 CML patients retrospectively. These patients, 4 females, 11 males, had undergone BMT during the first chronic phase after a preparative regimen consisting of total body irradiation (TBI) and cyclophosphamide; median age at BMT was 38 years (range 20-49 years). At the time of this study, 8 patients were in cytogenetic and/or clinical remission. Seven patients relapsed after BMT; all presented with Ph-chromosome-positive metaphases and BCR-ABL-positive cells at the time of relapse. In only 1 patient in hematologic remission was no positive PCR analysis obtained in the two samples tested. However, 5 patients have remained or became Ph-chromosome and/or PCR-positive after BMT without clinical symptoms of disease. In samples from another patient, transient presence of leukemic cells was observed only early after BMT. Clinically, these patients were relapse free at days 3,055, 2,581, 2,252, 1,846, 1,839, 1,747, and 1,173 after BMT, respectively. Based on these data, the presence of single BCR-ABL-positive cells > 1 year after BMT has no prognostic significance.
authors.affiliation: Institut für Molekularbiologie, (Tumorforschung), Essen, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Diekmann
authors.forename: D W
authors.initials: DW
authors.lastname: Beelen
authors.forename: K
authors.initials: K
authors.lastname: Quabeck
authors.forename: R
authors.initials: R
authors.lastname: Becher
authors.forename: H
authors.initials: H
authors.lastname: Schulte Holthausen
authors.forename: R
authors.initials: R
authors.lastname: Bützler
authors.forename: U W
authors.initials: UW
authors.lastname: Schaefer
authors.forename: B
authors.initials: B
authors.lastname: Opalka
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis; D012334:RNA, Neoplasm / Q000235:genetics; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D012334:RNA, Neoplasm; D016044:Fusion Proteins, bcr-abl